Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance
|
|
|
- Elaine Mason
- 5 years ago
- Views:
Transcription
1 Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance Dan G. Duda, DMD, PhD Harvard Medical School New Cancer Targets NCT Conference Sesptember 23, 2013
2 Conflicts of Interest None
3 Tumor Microenvironment Shapes Tumor Progression and Response to Therapy Courtesy of Dr. Lance L. Munn
4 Successful Phase III Trials of Antiangiogenics DRUG INDICATION IMPROVEMENT IN RR* (%) IMPROVEMENT IN PFS* (MONTHS) IMPROVEMENT IN OS* (MONTHS) BEVACIZUMAB Metastatic colorectal cancer (with chemotherapy) Metastatic non-squamous NSCLC (with chemotherapy) NS Metastatic breast cancer (with chemotherapy) NS Recurrent GBM (monotherapy) NS NS NS Currently only phase 2 data reported Metastatic RCC (with IFNα) NS NS SUNITINIB Metastatic RCC GIST NS PNET ? SORAFENIB Metastatic RCC NS Unresectable HCC 1 NS 2.8 Unresectable HCC PAZOPANIB Metastatic RCC N/A Advanced soft tissue sarcoma NS VANDETANIB Advanced medullary thyroid cancer N/A AXITINIB Advanced RCC N/A REGORAFENIB Chemo-refractory metastatic colorectal cancer AFLIBERCEPT Chemo-refractory metastatic colorectal cancer CABOZANTINIB Advanced medullary thyroid cancer NS RAMUCIRUMAB Metastatic gastric and gastroesophageal junction cancers* Updated from Carmeliet & Jain, Nature (2011)
5 Successful Phase III Trials of Anti-cancer Targeted Agents DRUG APPROVED INDICATION IMPROVEMENT IN RR* (%) IMPROVEMENT IN PFS* (MONTHS) IMPROVEMENT IN OS* (MONTHS) CETUXIMAB Metastatic colorectal cancer (with chemotherapy) (NS) 10 0 NS Metastatic non-squamous NSCLC (with chemotherapy) NS 1.2 Metastatic head and neck cancer (with radiation) NS 2.7 ELOTINIB TRASTUZUMAB LAPATINIB Metastatic non-squamous NSCLC (monotherapy) Metastatic pancreatic adenocarcinoma (with chemotherapy) Metastatic HER2+ breast carcinoma (with chemotherapy) Advanced HER2+ gastric carcinoma (with chemotherapy) Metastatic breast carcinoma (with chemotherapy) NS GEFITINIB VEMURAFENIB CRIZOTINIB VISMODEGIB Metastatic non-squamous NSCLC (versus chemotherapy) Japanese population Metastatic non-squamous NSCLC (versus chemotherapy) Metastatic melanoma with the BRAF V600E mutation ALK-positive non-squamous NSCLC Metastatic basal cell carcinoma (NS) 9.7 NS NS No phase III data available No phase III data available
6 Multidisciplinary Translational Trials Agent / Cancer Type Rectal Cancer Ovarian Cancer Breast Cancer Liver cancer Sarcoma Brain tumors Lung Cancer Schwannoma Insulinoma Bevacizumab (Genentech) Phase I/II Completed Phase II Completed Phase II Completed (ER+ & TN) Phase II Planned (HER2+) Phase II Completed Phase II Ongoing Phase II Completed Phase I Completed Phase II Completed Cediranib (AstraZeneca) Phase II Completed (HCC) 3 x Phase II Completed Phase III Completed Sunitinib (Pfizer) Sorafenib (Bayer/Onyx) Phase II Completed (HCC) Phase II Ongoing (HCC) Phase II Completed Vandetanib (AstraZeneca) Phase II Completed Phase II Completed Vatalanib (Novartis) Ramucirumab (ImClone) Plerixafor (Genzyme) & Bevacizumab Phase II Completed (HCC) Phase I Completed Phase II Ongoing Cabozantinib Phase II Ongoing Phase II Planned (CCA) Phase II Ongoing Highlighted trials analyses ongoing
7 Candidate Biomarkers Exist Duda, Angiogenesis Foundation e-publication CME series 2011
8 Clinical studies at MGH and DFCI Agent / Cancer Type Rectal Cancer Sarcoma Brain tumors Pancreatic Cancer Prostate Cancer HCC Radiation with bevacizumab (Genentech) Phase II Completed Phase II Completed Phase II Ongoing Radiation with cediranib (AstraZeneca) 2 x Phase II Completed Radiation with vatalanib (Novartis) Phase I Completed Radiation therapy Phase II Completed* Study off trial Phase II planned & Phase II ongoing* *Proton beam therapy &Radium-223 chloride (Ra-223)
9 Challenges How do we personalize these therapies? How do we schedule them with radiation therapies? How do these therapies work and how do they fail?
10 Weinberg & Hanahan. Hallmarks of cancer: the next generation. Cell 2011
11 Overview
12 Overview 1. Treatment resistance: Role of inflammatory factors
13 Overview 1. Treatment resistance: Role of inflammatory factors 2. Treatment resistance: Role of paracrine signals
14 Overview 1. Treatment resistance: Role of inflammatory factors 2. Treatment resistance: Role of paracrine signals 3. Concluding thoughts
15 How Relevant is Vasculogenesis in Tumors? Nature Reviews Neuroscience 2007
16 BMDC Contribution to Tumor Vessels Ang1 CD31- Tie2+ CD31+ Tie2+ Jain & Duda, Cancer Cell 2003
17 Tie2-GFP and Actb-GFP BMT Models to Detect BMD-ECs Duda et al., Blood 2006
18 Is Vasculogenesis Mediating Treatment Resistance? Nature Reviews Neuroscience 2007
19
20 LI Does Not Significantly Affect the Vasculature but Increases Myeloid BMDC Infiltration
21 How do inflammatory factors impact tumor resistance?
22 Effect of Myelosuppression on Tumor Growth I II
23 Effect of Myelosuppression on Tumor Growth I II
24 54A Lung Tumor Growth After 20Gy of LI
25 SDF1α expression 2 days after 20Gy of LI
26 Only concomitant CXCR4 Blockade Delays Tumor Growth MCa8 mammary carcinoma in FVB mice Kozin et al., Cancer Res 2010
27 Only concomitant CXCR4 Blockade Delays Tumor Growth MCa8 mammary carcinoma in FVB mice Kozin et al., Cancer Res 2010
28 Proposed Model of Tumor Growth after Irradiation JNCI J Natl Cancer Inst 2012;104: The Author Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oup.com.
29 Phase I/II Trial of Bevacizumab with Chemoradiation in Advanced Rectal Cancer Willett et al., Nat Med 2004 Willett et al., J Clin Oncol 2005 Duda et al., J Clin Oncol 2006 Willett, Duda et al., J Clin Oncol 2009 Willett, Duda et al., Nat Clin Pract Oncol 2007 Xu, Duda et al., Cancer Res 2009 Willett et al., Oncologist 2010 Duda et al., Oncologist 2010
30 Laser Capture Micro-dissection of Macrophages and Cancer Cells from Serial Biopsies Fold change (qpcr) Xu, Duda et al., Cancer Res 2009 * p<0.05 ** p<0.01
31 On-treatment Increase in SDF1α as a Potential Escape Pathway for Anti-VEGF Therapy Cancer type Agent(s) plasma SDF1α Reference Locally advanced rectal cancer Bevacizumab with chemoradiation DFS Xu, Duda, di Tomaso et al, Cancer Res (2009) Locally advanced HER2 breast cancer Bevacizumab with chemotherapy pcr (in Triple Neg. pts.) Tolaney et al, ASCO (2012) Advanced HCC Sunitinib OS Advanced sarcoma Sorafenib RR Advanced GBM Cediranib Radiographic progression Zhu et al, Clin Oncol (2009) Raut, Boucher, Duda et al, PLoS One (2012) Batchelor et al, J Clin Oncol (2010)
32 di Tomaso et al., Cancer Res 2011; Lu-Emerson et al., Neuro-Oncol 2013
33
34 SDF1α (CXCL12) pathway BMS (MDX1338) Nox-A12 AMD3100 (pleraxifor) BKT140 CCX662 Duda D G et al. Clin Cancer Res 2011;17: by American Association for Cancer Research
35 How about metastasis formation?
36 Neoadjuvant Bevacizumab with Chemoradiation Does Not Prevent Metastasis Willett, Duda et al., Oncologist 2010
37 Neoadjuvant Bevacizumab with Chemoradiation Does Not Prevent Metastasis C-08 (2,672 pts) Willett, Duda et al., Oncologist 2010
38 Neoadjuvant Bevacizumab with Chemoradiation Does Not Prevent Metastasis C-08 (2,672 pts) AVANT (3,451 pts) Willett, Duda et al., Oncologist 2010
39 Dawson et al., Nature 2009 Duda et al., Cancer Res 2010
40 Does SDF1α/CXCR4 pathway mediate the involvement of BMDCs in metastasis?
41 Inducible CXCR4 deficiency Dawson, Duda et al., Nature 2009 Hiratsuka, Duda et al., PNAS 2011
42 CXCR4 blockade significantly inhibits lung metastasis after primary tumor resection TRAMP-C1 prostate cancer Number of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Volume of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Hiratsuka et al., PNAS 2011 *p < 0.05
43 CXCR4 blockade significantly inhibits lung metastasis after primary tumor resection TRAMP-C1 prostate cancer Number of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Volume of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Number of metastases * Volume of metastases * * 0 Ctrl BMT CXCR4-KO BMT CXCR4/TK-KO BMT 0 Ctrl BMT CXCR4-KO BMT CXCR4/TK-KO BMT E0771 breast cancer Hiratsuka et al., PNAS 2011 *p < 0.05
44 CXCR4 blockade significantly inhibits lung metastasis after primary tumor resection TRAMP-C1 prostate cancer AMD3100 (AMD) Number of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Volume of metastases Ctrl BMT * * CXCR4-KO CXCR4/TK-KO BMT BMT Number of metastases Ctrl BMT CXCR4-KO BMT * CXCR4/TK-KO BMT Volume of metastases Ctrl BMT * CXCR4-KO BMT * CXCR4/TK-KO BMT Number of metastases PBS (WT) AMD (WT) PBS (TK) * AMD (TK) Volume of metastases PBS (WT) AMD (WT) PBS (TK) * AMD (TK) E0771 breast cancer VEGFR1-TK-KO BMT (TK) Hiratsuka et al., PNAS 2011 *p < 0.05
45
46 BMDCs and SDF1a/CXCR4 may be valid targets for inihition of tumor resistance and distant progression
47 Targeting paracrine interactions
48 Does the tumor rely on host-derived signals for progression?
49 Phase I/ II Trial of Neoadjuvant Proton with Chemotherapy in Pancreatic Adenocarcinoma Proton Therapy (5 x 5 Gy QD) Capecitabine (825 mg/m 2 PO BID) Surgery Day Tissue Blood Hong et al., unpublished data
50 Local recurrence Hong et al., ASCO 2013
51 Local recurrence Distant metastasis Hong et al., ASCO 2013
52 Local recurrence Distant metastasis Hong et al., ASCO 2013
53 KRAS G12D mutation and elevated HGF are associated with poor survival 1.8 No KRAS G12D mutation KRAS G12D mutation 1.8 HGF 1500 pg/ml HGF>1500 pg/ml Overall Survival P=0.024 Overall Survival P= Follow-up Time (Months) Follow-up Time (Months) Hong et al., ASCO 2013
54 Are HGF and cmet expressed in PDAC?
55 Are HGF and cmet expressed in PDAC? HGF cmet!! Courtesy Dr. Deshpande (MGH)
56 PlGF/NRP1 in Medulloblastoma Snuderl et al, Cell 2013 NEJM 2013
57 Stroma-mediated signals may drive tumor progression as well as treatment resistance
58 Concluding thoughts
59 Concluding thoughts Host-derived factors and tumor stroma mediate cancer progression and therapeutic resistance
60 Concluding thoughts Host-derived factors and tumor stroma mediate cancer progression and therapeutic resistance Pathways of evasion should be confirmed in clinical studies, which in turn should inform preclinical studies
61 Concluding thoughts Host-derived factors and tumor stroma mediate cancer progression and therapeutic resistance Pathways of evasion should be confirmed in clinical studies, which in turn should inform preclinical studies Mechanistically based biomarkers of resistance may help guide trial design
62 Steele Lab at MGH
63 Steele Lab at MGH Funding R21CA139168, R01CA159258, P01CA80124 & Federal Share Proton Beam NCI Grants American Cancer Society RSG TBG American Association for Cancer Research Cancer Research Institute
64 MGH/DF Clinical Collaborators and Patients Agent / Cancer Type Rectal Cancer Brain tumors Breast Cancer HCC Sarcoma Ovarian Cancer Lung Cancer Schwannoma Bevacizumab (Genentech) Cediranib (AstraZeneca) Sunitinib (Pfizer) Willett Krop Zhu Yoon Horowitz Heist Plotkin Sorafenib (Bayer/Onyx) Batchelor Ramucirumab (ImClone) Eder Vatalanib (Novartis) Vandetanib (AstraZeneca) Gerstner Plerixafor (Genzyme) Meyerhardt Hong Proton Therapy Wen
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Targeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
European consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
Contemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned
The Role of Angiogenesis Inhibition in Breast Cancer Today: Lessons Learned Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Helen Diller Family Comprehensive
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
breast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
Thoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
New Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
NSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
DOI 10.1007/s10456-014-9420-y REVIEW PAPER Anti-angiogenic for cancer: current progress, unresolved questions and future directions Naveen S. Vasudev Andrew R. Reynolds Received: 15 July 2013 / Accepted:
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1101-7 Program Prior Authorization/Notification Medication Sutent (sunitinib malate) P&T Approval Date 8/2008, 6/2009, 6/2010,
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
Mechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
Angiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
ASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
Drug-drug interactions with oncolytics (in particular PPIs and TKIs)
Drug-drug interactions with oncolytics (in particular PPIs and TKIs) Prof. Ron Mathijssen, MD PhD Medical Oncologist/ Clinical Pharmacologist Erasmus MC Cancer Institute Rotterdam ICPAD Workshop November
Third Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
Novel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
Where Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Upregulates SDF1, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Upregulates SDF1, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer The Harvard community has made this article openly available.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1113-6 Program Prior Authorization/Notification Medication Votrient TM (pazopanib) P&T Approval Date 1/12/2010, 9/2010, 12/2010,
Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
Cancer Metronomic Therapy Milan, February 26, 2016
Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.
VEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
UnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
K-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
COME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Thyroid Cancer pathway development worksheet, v9 April 13, 2015 Required Structured Data: Stage Staging Components Staging Date Histology Quality Measure(s): Staging (clinical or pathologic)
HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
Other Driver Mutations: cmet, B-RAF, RET, NTRK
Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College
Savolitinib clinical trials June 2016 update
Savolitinib clinical trials June 2016 update List of abbreviations BID Twice Daily MET Aberation of c-met/hgf CRC Colorectal Cancer MTD Maximum Tolerated Dose DoR Duration of Response NSCLC Non-Small Cell
London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
HER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes
Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director
Nintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
EGFR in Gastric Cancer. Manuel Hidalgo, M.D., Ph.D. The Johns Hopkins University Baltimore, MD USA
EGFR in Gastric Cancer Manuel Hidalgo, M.D., Ph.D. The Johns Hopkins University Baltimore, MD USA Agenda Brief introduction to the EGFR. Rationale to target the EGFR in gastric and other upper GI cancers.
Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
Development of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
Critical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
Current experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III. Tarceva TM
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III Tarceva TM Tarceva TM (erlotinib HCl) High-affinity, reversible inhibitor of HER1/EGFR Tyrosine
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Objectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
RT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
Design considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
Posters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
ESMO 13th World Congress on Gastrointestinal Cancer
ESMO 13th World Congress on Gastrointestinal Cancer 22-25 June, 2011 Barcelona, Spain INTRODUCTION The ESMO World Congress on Gastrointestinal Cancer took place in Barcelona from the 22nd until the 25th
CTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
EGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
What s New in Clinical Oncology? Highlights from the 2009 ASCO Annual Meeting
Clin Oncol Cancer Res (2009) 6: 235-240 DOI 10.1007/s11805-009-0235-3 235 What s New in Clinical Oncology? Highlights from the 2009 ASCO Annual Meeting Xiaolong Jiao Yilian Yuan ABSTRACT This review summarizes
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Montor et al. Molecular Cancer (2018) 17:55 https://doi.org/10.1186/s12943-018-0792-2 REVIEW Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal
CUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
Medicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
Systemic Cytotoxic Therapy in advanced HCC
Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
Immunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
General Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
A Brief Overview of Screening and Management of Colorectal Cancer
A Brief Overview of Screening and Management of Colorectal Cancer Gentry King MD Assistant Professor Hematology and Medical Oncology University of Colorado Disclosures Nothing to disclose Objectives Review
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
Second - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
Head and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
Angiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
Immunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
Gastric and Colon Cancer. Dr. Andres Wiernik 2017
Gastric and Colon Cancer Dr. Andres Wiernik 2017 GASTRIC CANCER Gastric Cancer Classification Epidemiology General principles of Management 25% GE Junction Gastric Cancer 75% Gastric Cancer Epidemiology
Molecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
Selecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens